ÂÜÀòÂÒÂ×

Edel Mullen is an experienced professional in the biopharmaceutical industry, currently serving as Director of Drug Product Technologies and Director of Rare Disease at Amgen since October 2023. Previous roles include Director of Biologics CMC Technical Operations and Associate Director of Technical Development at Horizon from November 2020 to October 2023, and a Principal Scientist at Pfizer from February 2019 to December 2020, where expertise in protein mass spectrometry and biophysical analytics was applied to support large molecule discovery. Additional roles include membership in industry organizations such as CASSS and the Irish Mass Spectrometry Society, and experience in technical operations, manufacturing, and proteomics at companies including Abbott and NUI Galway. Edel Mullen holds an MBA from the Isenberg School of Management, a Lean Six Sigma Green Belt, a PhD in Proteomics and Biochemistry, and a BSc in General Science with double honors in Biology and Chemistry from Maynooth University.